JO3522B1 - تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له - Google Patents

تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له

Info

Publication number
JO3522B1
JO3522B1 JOP/2015/0030A JOP20150030A JO3522B1 JO 3522 B1 JO3522 B1 JO 3522B1 JO P20150030 A JOP20150030 A JO P20150030A JO 3522 B1 JO3522 B1 JO 3522B1
Authority
JO
Jordan
Prior art keywords
plp
dependent enzyme
pharmaceutical composition
cofactor
erythrocytes
Prior art date
Application number
JOP/2015/0030A
Other languages
English (en)
Inventor
Vanessa Bourgeaux
Fabien Gay
Thomas Cortese
Yann Godfrin
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729647&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3522(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma filed Critical Erytech Pharma
Application granted granted Critical
Publication of JO3522B1 publication Critical patent/JO3522B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01005—Tyrosine transaminase (2.6.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلانية محتوية على إنزيم أساسه PLP واختياريًا العامل المشترك الخاص به، بَيرِيدُكْسال فوسفات (PLP)، و/أو مادة منتجة لـ PLP من فوسفات أو من غير الفوسفات، استخدامه كعقار، طريقة إنتاجه وطريقة علاجية ذات صلة به. تشتمل التركيبة الصيدلانية على كريات حمراء ومادة ناقلة مقبولة صيدلانيًا، الكريات الحمراء التي تُغلّف إنزيم أساسه PLP. يمكن أن يكون الإنزيم الذي أساسه PLP عبارة عن مِثيونيناز، تيروزين فينول - لياز، تيروزين ناقلة الأمين أو سيسْتاتيُونين بيتا - سينثاز.
JOP/2015/0030A 2014-02-12 2015-02-12 تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له JO3522B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1451100A FR3017299B1 (fr) 2014-02-12 2014-02-12 Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur

Publications (1)

Publication Number Publication Date
JO3522B1 true JO3522B1 (ar) 2020-07-05

Family

ID=50729647

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0030A JO3522B1 (ar) 2014-02-12 2015-02-12 تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له

Country Status (17)

Country Link
US (3) US10046009B2 (ar)
EP (2) EP3104875B1 (ar)
JP (1) JP6563958B2 (ar)
KR (1) KR102354103B1 (ar)
CN (2) CN106255506B (ar)
AU (2) AU2015217045B2 (ar)
BR (1) BR112016017337B1 (ar)
CA (1) CA2938469C (ar)
CL (1) CL2016002020A1 (ar)
ES (1) ES2808849T3 (ar)
FR (1) FR3017299B1 (ar)
IL (1) IL246941B (ar)
JO (1) JO3522B1 (ar)
MX (1) MX2016010235A (ar)
RU (2) RU2744659C2 (ar)
SG (2) SG11201606264SA (ar)
WO (1) WO2015121348A2 (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
DK3125927T3 (da) 2014-04-01 2021-04-19 Rubius Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulering
EP3187190A1 (en) 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
RS62939B1 (sr) 2016-01-11 2022-03-31 Rubius Therapeutics Inc Kompozicije i metode u vezi sa multimodalnim terapijskim ćelijskim sistemima u indikacijama kancera
CN109562185A (zh) 2016-06-02 2019-04-02 赛诺菲 药剂与能够结合葡萄糖感应蛋白的部分的新颖缀合物
US11744859B2 (en) * 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
US11001826B2 (en) 2017-10-19 2021-05-11 Anticancer, Inc. Orally administered composition to lower serum methionine levels and method of use
KR20200095507A (ko) 2017-12-01 2020-08-10 사노피 글루코오스 감지 단백질에 결합할 수 있는 모이어티 및 약제의 신규 접합체
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020099592A1 (en) 2018-11-15 2020-05-22 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
KR20220005028A (ko) 2019-04-26 2022-01-12 루비우스 테라퓨틱스, 아이엔씨. 탈핵 적혈구를 포함하는 조성물
AU2020283752A1 (en) 2019-05-24 2021-12-23 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells
AU2020379755A1 (en) 2019-11-04 2022-05-26 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using myo-inositol
EP4055148A1 (en) 2019-11-04 2022-09-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using taurine or hypotaurine
US20230226218A1 (en) 2020-05-11 2023-07-20 Erytech Pharma Red Cell Extracellular Vesicles (RCEVs) Containing Cargoes and Methods of Use and Production Thereof
WO2022150578A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. Methods of treating a tumor in a human subject
WO2022150569A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF
TW202304482A (zh) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 於個體中增加nkg2d陽性淋巴球之方法及其用途
CA3220735A1 (en) * 2021-05-21 2022-11-24 Codexis, Inc. Engineered methionine gamma lyase variants
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
CN113481253B (zh) * 2021-06-09 2022-05-24 连云港杰瑞药业有限公司 生物催化制备磷酸吡哆醛的方法
WO2023067200A1 (en) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1354204A (fr) 1963-01-22 1964-03-06 Auxiliaire De L Entpr Soc Dispositif de prévention d'accident pour benne de chargement notamment d'une bétonnière
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US5631271A (en) * 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US6475767B1 (en) 1997-03-13 2002-11-05 Shionogi & Co., Ltd. Process for producing L-methionine γ-lyase crystals
WO2002029040A2 (en) * 2000-10-06 2002-04-11 Millennium Pharmaceuticals, Inc. 25219, a novel human aminotransferase and uses therefor
WO2005045055A2 (en) 2003-07-31 2005-05-19 Anticancer, Inc. The use of plp with peg-rmetase in vivo for enhanced efficacy
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
RU2362572C2 (ru) * 2007-07-17 2009-07-27 Юрий Георгиевич Каминский Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
US20100316620A1 (en) 2008-02-13 2010-12-16 Vanessa Bourgeaux Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
CN101429506A (zh) * 2008-12-15 2009-05-13 吉林大学 基于红细胞载体的fish-in-net固定化酶
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
PT2493487T (pt) 2009-10-27 2016-11-08 Erytech Pharma Composição para induzir uma tolerância imunitária específica
CN104394884A (zh) 2012-03-21 2015-03-04 爱瑞泰克药物公司 用于治疗急性髓细胞白血病(aml)的药剂
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Also Published As

Publication number Publication date
RU2016133315A3 (ar) 2018-09-26
RU2016133315A (ru) 2018-02-16
SG11201606264SA (en) 2016-08-30
US20180344771A1 (en) 2018-12-06
RU2697086C2 (ru) 2019-08-12
AU2018201237B2 (en) 2019-09-26
ES2808849T3 (es) 2021-03-02
AU2015217045A1 (en) 2016-08-18
MX2016010235A (es) 2016-10-28
KR102354103B1 (ko) 2022-01-24
BR112016017337B1 (pt) 2022-08-09
SG10201907367QA (en) 2019-09-27
CN111358941A (zh) 2020-07-03
BR112016017337A2 (ar) 2017-08-08
CN111358941B (zh) 2023-12-01
JP6563958B2 (ja) 2019-08-21
KR20160121532A (ko) 2016-10-19
US20160361361A1 (en) 2016-12-15
AU2015217045B2 (en) 2018-03-08
US20210008114A1 (en) 2021-01-14
CN106255506B (zh) 2020-04-14
WO2015121348A2 (en) 2015-08-20
US10780126B2 (en) 2020-09-22
FR3017299B1 (fr) 2018-05-18
EP3104875B1 (en) 2020-05-06
RU2019123935A3 (ar) 2020-03-26
IL246941A0 (en) 2016-09-29
US11458170B2 (en) 2022-10-04
RU2744659C2 (ru) 2021-03-12
CA2938469A1 (en) 2015-08-20
CA2938469C (en) 2023-03-14
IL246941B (en) 2019-09-26
RU2019123935A (ru) 2019-10-03
US10046009B2 (en) 2018-08-14
JP2017506260A (ja) 2017-03-02
FR3017299A1 (fr) 2015-08-14
CL2016002020A1 (es) 2017-06-23
AU2018201237A1 (en) 2018-03-15
EP3718562A1 (en) 2020-10-07
WO2015121348A3 (en) 2015-10-08
CN106255506A (zh) 2016-12-21
EP3104875A2 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
JO3522B1 (ar) تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2018004328A (es) Composiciones farmaceuticas estabilizantes de camptotecina.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
WO2014015056A3 (en) Anti-mucus drugs and uses therefor
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
NZ726131A (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
NZ726129A (en) Process for obtaining optically active pirlindole enantiomers and salts thereof
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
WO2016126572A3 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
MY174063A (en) Poly-l-glutamic acid drug carrier for targeting and treating kidney diseases